Unraveling the Implications of ctDNA As a Biomarker Using Tumor-Informed MRD for Solid Tumors

Time: 2:00 pm
day: Day Two


• ctDNA is a good biomarker in MRD determination, the prognosis value of using ctDNA to determine MRD status in solid tumor had been demostrated in many clinical study.

• The sensitivity of the MRD test plays a crucial role in detecting ctDNA in patients due to the extremely low abundance of ctDNA in blood.

• brPROPHET adopts a tumor-informed personalized panel approach on MRD assessment with a limit of detection of 40 ppm, which its capabilities of prognosis prediction and monitoring therapeutic response have been shown in clinical studies on different cancer types